How do I manage refractory invasive pulmonary aspergillosis

Area of Science:

• Medical Mycology
• Infectious Diseases
• Hematology Oncology

Background:

• Invasive aspergillosis presents a significant challenge in immunocompromised patients, particularly those with hematologic malignancies and transplant recipients.
• Outcomes are notably worse for patients who do not respond to initial antifungal treatments.
• Refractory disease necessitates specialized diagnostic and management strategies.

Purpose of the Study:

• To offer clinical guidance for diagnosing and managing invasive pulmonary aspergillosis that is refractory to standard treatments.
• To review current evidence and propose an evidence-based approach for complex cases.

Main Methods:

• A comprehensive literature review was conducted using PubMed.
• Included were original research articles, meta-analyses, and systematic reviews.
• Focused on diagnostic criteria and treatment evidence for primary and refractory invasive pulmonary aspergillosis.

Main Results:

• Diagnostic evaluation is crucial to confirm aspergillosis and rule out other infections in patients with worsening symptoms despite antifungal therapy.
• Treatment decisions for refractory cases must be individualized based on patient factors and disease characteristics.
• Experimental antifungal agents may play a role in select situations.

Conclusions:

• Individualized treatment is key for refractory invasive pulmonary aspergillosis.
• Therapeutic options include switching to alternative azoles, using lipid formulations of amphotericin B, or employing combination antifungal regimens.
• Further research into novel antifungal agents is warranted.